GABRB2
ENSG00000145864
Target class
Ion channel
Chromosome
5
Approved drugs
56
Clinical candidates (approved and in development)
67
- Approved drugs
- 56
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 67
- Chemical probe available
- No
- Target name
- GABRB2
- Gene name
- Gamma-aminobutyric acid type A receptor subunit beta2
- Gene symbol
- GABRB2
- Protein name
- Gamma-aminobutyric acid receptor subunit beta-2 (GABA(A) receptor subunit beta-2) (GABAAR subunit beta-2)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 14
- Highest tissue expression
- 74.29
- Tissue specificity (Gini)
- 0.872
- Tissue specificity (tau)
- 0.955
- KEGG gene identifiers
- hsa:2561
- Protein interaction confidence
- 0.84855
- Protein interaction partners
- 20
- R-HSA-1236394
- R-HSA-977443
- End position
- 161549044
- Start position
- 161288429
- Chromosome
- 5
- Strand
- Reverse
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Cytoplasmic vesicle membrane .
- PubMed 29950725
- PubMed 19763268
- PubMed 8264558
- Tissue specificity (tau)
- 0.955488
- Expression inequality (Gini)
- 0.872065
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 74.29
- Brain - Cerebellum
- 51.22
- Brain - Frontal Cortex (BA9)
- 39.5
- Brain - Cortex
- 20.08
- Brain - Anterior cingulate cortex (BA24)
- 14.87
Expression in transcripts per million
- Brain - Cerebellar Hemisphere74.29
- Brain - Cerebellum51.22
- Brain - Frontal Cortex (BA9)39.5
- Brain - Cortex20.08
- Brain - Anterior cingulate cortex (BA24)14.87
- Brain - Nucleus accumbens (basal ganglia)8.74
- Brain - Caudate (basal ganglia)8.28
- Brain - Amygdala5.93
- Brain - Hippocampus5.72
- Brain - Putamen (basal ganglia)5.53
- Brain - Hypothalamus4.07
- Brain - Substantia nigra1.93
- Spleen1.45
- Adrenal Gland1
- Lung0.73
- Adipose - Visceral (Omentum)0.64
- Brain - Spinal cord (cervical c-1)0.54
- Testis0.51
- Minor Salivary Gland0.46
- Pituitary0.38
- Adipose - Subcutaneous0.36
- Cervix - Endocervix0.23
- Breast - Mammary Tissue0.19
- Kidney - Medulla0.19
- Kidney - Cortex0.19
And 29 more, listed on the interactive page.
- GO:0007214
- GO:0007268
- GO:1902476
- GO:1904862
- GO:0005886
- GO:0043197
- GO:0045211
- GO:0070062
- GO:0004890
- GO:0016917
- GO:0022851
Related records
Trials (3,892)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
Drugs (77)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist